Express Pharma

Biogen moves forward with potential Alzheimer’s drug, seeks US FDA’s approval

The drug, aducanumab, has had a tumultuous journey, with promising early data raising hopes and Biogen’s share price, only to be dashed by disappointment in later trials

0 778